Good call with lots of clarity. Will want to listen to it a few times.
Just a quick note to all those overestimating Elite's revenue calcs. We sell Vyvanse at about 10% of brand. This is how the market shrinks. We aren't capturing higher pricing as I would have expected and walk down price. We're entering market at very low price to capture and keep market share. So 1% of market for Elite isn't 40M, it's significantly lower, but Vyvanse will be our biggest product by far. Exciting days ahead just need to tamper down expectations. We won't be getting to 1B for some of those who thought we will.
Market Data 
Markets 
AI
